louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00607334: Experimental Word Learning in Children With and Without Language Impairment
Official title: Experimental Word Learning in Children With Normal Development and Children With Language Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Developmental Language Disorders
Keywords: Child Language
Language Therapy
Vocabulary
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2008-02-05
Enrollment: 51
Sex: ALL
Minimum age (years): 36
Maximum age (years): 47
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the performances of normally developing children and children with Language Impairment (LI) in three different experimental settings designed to promote vocabulary acquisition. This comparison will also provide evidence to support different intervention approaches designed to increase vocabulary abilities, which has been proved to be one of the major deficits of young children with LI.


Eligibility criteria: Inclusion Criteria:

* For GP subjects: - diagnosis of Language Impairment
* enrolled in language therapy
* age between 3:0 (years:months) and 3:11
* For GC subjects: - normal performance in a language screening procedure
* normal performance in an expressive vocabulary test

Exclusion Criteria:

* For GP subjects: - hearing impairments
* diagnosed neurological or behavioral conditions
* major cognitive impairment
* For GC subjects: - communication complaints from caregivers
* history of previous enrollment in language therapy

Primary outcomes:
measure: Performance on a post-test administered after every word-learning session.
timeFrame: Three weeks
Secondary outcomes:
measure: Occurence of correct spontaneous productions of the taught words during the experimental procedure
timeFrame: Three weeks
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: USP - Faculty of Medicine - Department of Physiotherapy, Communication Sciences and Disorders, Occupational Therapy
state: SP
Study officials:
affiliation: University of Sao Paulo
name: Debora M. Befi-Lopes, PhD
role: STUDY_CHAIR
affiliation: University of Sao Paulo
name: Juliana P. Gândara, PhD student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01821534: Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2013-04-01
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy Volunteers

Brief summary: This study will evaluate the inter-rater and intra-rater reliability of a Masseter Muscle Prominence Scale for evaluating a patient's muscle prominence and a Lower Shape Classification for evaluating a patient's lower facial shape.


Eligibility criteria: Inclusion Criteria:

-sufficient visual acuity without the use of glasses or with contact lenses to self-assess lower facial shape in a mirror

Exclusion Criteria:

* infection of the mouth or gums, or facial skin infection requiring antibiotics
* planned dental or facial procedure
* unwillingness to be photographed and have the photos used for research, training, or educational purposes

Primary outcomes:
measure: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS)
timeFrame: Day 1
measure: Intra-rater Reliability Using a MMPS
timeFrame: Day 1
measure: Inter-rater Reliability Using a Lower Facial Shape Classification (LFSC)
timeFrame: Day 1
measure: Intra-rater Reliability Using a LFSC
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01791634: Prospective, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle
Official title: Prospective, Randomized, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hallux Valgus
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
Collaborators: name: Arthrex, Inc.
First posted: 2013-02-15
Enrollment: 75
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Is there a difference in clinical outcome measures as assessed by the AOFAS, SF-36 and Visual Analogue Scale of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with LPS system versus the proximal chevron osteotomy?

Detailed description: Is there a difference in radiologic outcomes of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with LPS system versus proximal wedge osteotomy? Is there a difference in surgical times or surgeon procedure preference in the treatment of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with LPS system versus proximal wedge osteotomy? Is there a difference in complication rates of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with LPS system versus proximal wedge osteotomy?

Eligibility criteria: Inclusion Criteria:

* age (\> 16 years of age) moderate to severe hallux valgus angle \[HVA\] of \>30º with increased intermetatarsal angles \[IMA\] of \>13º
* persistent incapacitating symptoms despite non-operative treatment (shoe wear modification, orthoses, non-steroidal anti-inflammatory drugs and restricted activity)

Exclusion Criteria:

* degenerative arthritis of 1st metatarsophalangeal (MTP) joint
* neuropathic patients
* diabetes mellitus
* peripheral vascular disease
* previous 1st metatarsal, hallux or MTP joint surgery
* active or recent foot/toe infection
* currently participation in a another clinical trial
* Worker's Compensation Board patients.

Primary outcomes:
measure: Short Form 36
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Halifax Infirmary
state: Nova Scotia
Study officials:
affiliation: Nova Scotia Health Authority
name: Dr Mark A Glazebrook, MSc PhD Dip Sports Med MD,FRCS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01708434: Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Knees
Official title: Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Knees
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Laxity
Keywords: Skin laxity
Knees
Lead sponsor: Merz North America, Inc.
Sponsor class: INDUSTRY
First posted: 2012-10-17
Enrollment: 30
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Enrolled subjects will receive one bilateral Ulthera® treatment on the knees. Up to 30 subjects will be enrolled. Study photos will be obtained prior to study treatment, immediately following study treatment, and at each post-treatment follow-up visit. Follow-up visits will occur at 90 and 180 days post-treatment.

Detailed description: This pilot study is a prospective, single-center clinical trial of the Ulthera® System for treating skin laxity on the knees. Global Aesthetic Improvement Scale scores and Patient Satisfaction questionnaires will be obtained at each follow-up visit.

Eligibility criteria: Inclusion Criteria:

* Female, aged 30 to 65 years.
* Subject in good health.
* Mild to moderate skin laxity around the knees.
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.

Exclusion Criteria:

* Presence of an active systemic or local skin disease that may affect wound healing.
* Excessive subcutaneous fat around the knees.
* Excessive skin laxity around the knees.

Primary outcomes:
measure: Improvement in overall lifting and tightening of knee skin laxity.
timeFrame: 90 and 180 days post-treatment
Secondary outcomes:
measure: Overall improvement in skin laxity.
timeFrame: 90 and 180 days post-treatment
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Clinical Research Center
state: Tennessee
Study officials:
affiliation: Tennessee Clinical Research Center
name: Michael Gold, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gold MH, Sensing W, Biron J. Use of micro-focused ultrasound with visualization to lift and tighten lax knee skin (1.). J Cosmet Laser Ther. 2014 Oct;16(5):225-9. doi: 10.3109/14764172.2014.949273. Epub 2014 Sep 2.
Clinical trial NCT04152434: Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy
Official title: Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy; a Real World Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Refractory Chronic Migraine
Lead sponsor: Clinique des Céphalées de Montréal
Sponsor class: OTHER
First posted: 2019-11-05
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with more than 15 migraine days per month, receiving Botox, or an oral preventive treatment, or without any preventive therapy. Have failed more than 3 preventive treatments previously

Brief summary: Treatment of chronic migraineurs who have failed more than 3 preventive drugs with Erenumab alone, to reduce frequency of monthly migraine days or as an add on therapy

Detailed description: The investigators treated chronic migraineurs that have failed more than 3 preventive drugs with Erenumab alone or as an add on therapy to: Reduce the frequency of monthly migraine days, to evaluate If the add on of Erenumab to another preventive therapy is superior to Erenumab alone, and assess all adverse events related to the use of Erenumab.

Migraineurs with 15-30 migraie days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly migraine days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)

Eligibility criteria: Inclusion Criteria:

* chronic migraineurs with failure to more than 3 preventive treatments
* Naive to anti CGRP monclonal antibodies

Exclusion Criteria:

* episodic migraineurs,
* Other headache types

Primary outcomes:
measure: Change in monthly migraine days
timeFrame: 5 months
Secondary outcomes:
measure: Change in frequency of monthly migraine days adding Erenumab to another preventive treatment,
timeFrame: 5 months
measure: Change in the frequency of monthly migraine days adding Erenumab to another preventive treatment
timeFrame: 5 months
measure: change in frequency of monthly migraine days with Erenumab alone
timeFrame: 5 months
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Guy Pierre Boudreau
state: Quebec
Study officials:
affiliation: Clinique des Céphalées de Montréal
name: Guy P Boudreau, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06731634: De Quervain Syndrome Among Medical Students with Smart Phone Addiction
Official title: Prevalence of De Quervain' S Tenosynovit's Syndrome Among Egyptian Medical Students with Smart Phone Addiction
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: De Quervain Tenosynovitis
Smartphone Addiction
Keywords: De quervain tenosynovitis
Egyptian medical students
Cairo University
Smartphone addiction
Prevelance
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-12
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study population will be recruited from the medical collages of Cairo University in Egypt

Brief summary: To investigate the prevelance of the de quervain tenosynovitis among the Egyptian medical students with smartphone addiction

Detailed description: Addictive participants will be assigned and enrolled in the study according to there addiction score on smartphone addiction scale.

Participants will receive a Finkelstein test for both dominant and non dominant hand for the de quervain tenosynovitis.

Then the strentgh of both hand grip and pinch grip for both hands will be tested using hand grip strength dynamometer and pinch strentgh dynamometer.

Eligibility criteria: Inclusion Criteria:

* Asymptomatic students with normal healthy state
* Any student in all the academic years with age 18-25
* Addictive smart phone users with score over 31 for male and 33 for female students in smart phone addiction scale.
* Who own or use mobile.
* Both genders: male and female
* Willing to participate.
* Egyptian students

Exclusion Criteria:

* Those who don't have mobile phone.
* Any previous injury or trauma or surgery and a history of rheumatoid arthritis, osteoarthritis, and deformities and changes in the shape of the finger joints.
* Those who are not willing to participate.
* Non-Egyptian students.

Primary outcomes:
measure: Dominant hand grip strength and Non-Dominant hand grip strength by the using of jamar hydraulic grip strength dynamometer
timeFrame: 1 Day
measure: Dominant hand pinch strength and non-dominant hand pinch strength by the using of jamar hydraulic pinch strength dynamometer
timeFrame: 1 Day
Secondary outcomes:
measure: The degree of pain during the finkelstein test by the using of visual analoug scale
timeFrame: 1 Day
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02406534: A Prospective, Observational Study of COPD Patients in U.S. Hospitals
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: EPI-Q
Sponsor class: OTHER
First posted: 2015-04-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD patients admitted for a COPD exacerbation.

Brief summary: This is an observational study to evaluate the relationship between pulmonary function and the patient reported health-related quality of life (HRQoL) and chronic obstructive pulmonary disease (COPD) related admissions. Patients with COPD will be approached to participate in the study. Pulmonary function will be measured on consented, eligible patients. The pulmonary function measurement collected will be used for cohort assignment. The prospective follow up period will monitor the cohorts for evidence of readmission and to assess HRQoL.


Eligibility criteria: Inclusion Criteria:

≥ 18 years of age Fluent in English Current hospital admission is for COPD Diagnosis of COPD for at least 1 year prior to enrollment

Exclusion Criteria:

Unwilling or unable to provide informed consent

Primary outcomes:
measure: COPD related readmissions
timeFrame: 6 months
measure: Health related quality of life (HRQoL)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: EPI-Q
name: Valerie Caroselli
role: STUDY_DIRECTOR
References:
Clinical trial NCT05080634: Analysis of Prevalence and Risk Factors Associated With Gastroesophageal Reflux Disease and Esophagitis After Peroral Endoscopic Myotomy
Official title: Analysis of Incidence and Risk Factors Associated With Gastroesophageal Reflux Disease and Esophagitis After Peroral Endoscopic Myotomy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Achalasia
GERD
Keywords: Peroral endoscopic myotomy
High-resolution esophageal manometry
Lead sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Sponsor class: OTHER
First posted: 2021-10-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients treated at a single center who had a complete GERD evaluation after POEM will be included in the study. Demographics, preoperative and follow-up data, results of functional studies and procedural data will be collected and analyzed.

Brief summary: Achalasia is an uncommon disorder that results from the degeneration of ganglion cells of the myenteric plexus in the lower esophageal wall. Peroral endoscopic myotomy (POEM) is a minimally invasive procedure capable of overcoming limitations of achalasia treatments. This study aimed to: 1) identify the prevalence of reflux esophagitis and asymptomatic GERD in patients who underwent POEM, and 2) evaluate patient and intraprocedural variables associated with post-POEM GERD.


Eligibility criteria: Inclusion Criteria:

1. Males and females who are 18 years of age and older and are willing to sign an Informed Consent Form (ICF)
2. Achalasia patients who underwent POEM

Exclusion Criteria:

1. Lack of written consent for participation in the study
2. Conditions which are contraindication to Esophagogastroscopy and High-resolution Esophageal Manometry

Primary outcomes:
measure: The prevalence of gastroesophageal reflux after peroral endoscopic myotomy (POEM)
timeFrame: 36 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Maria Sklodowska-Curie Institute - Oncology Center
Study officials:
affiliation: The Maria Sklodowska-Curie National Research Institute of Oncology
name: Anna Chaber-Ciopińska, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00409734: Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis
Official title: Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pyloric Stenosis
Keywords: pyloric
stenosis
Lead sponsor: Maimonides Medical Center
Sponsor class: OTHER
First posted: 2006-12-11
Enrollment: 20
Sex: ALL
Minimum age (years): 2
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and female children age 2 weeks to 9 weeks, either with pyloric stenosis or without

Brief summary: The purpose of this study is to determine if there is an increase in the frequency of formula change in patients with pyloric sctenosis prior to being correctly diagnosed.

Detailed description: The study can be described as a prospective and retrospective study in which information will be gathered from questionnaires, analysis of medical records, and the information obtained from diagnostic procedures (i.e. Laboratory results, ultrasonography). The time of enrollment will be at the time of hospital admission for the study group and the control group. The length of time for which the patient will be involved with the study will coincide with the length of stay in the hospital. This will be a single center trial involving Maimonides Medical center. Approximately 50-100 subjects will be enrolled overall to give the study more credibility.

Methods and Procedures:

1. Study Participants: All patients admitted to Maimonides Medical Center with a diagnosis of pyloric stenosis two to nine weeks of age. Patients will be excluded from the study if there is a diagnosed milk allergy, history of prior abdominal surgery, or history of prematurity or metabolic disease. Controls will be made up of the same age range, with similar exclusion criteria, and will consist of patients admitted for other reasons than listed above, such as bronchiolitis and rule out sepsis.

2: Data: Data will be received through the completion of questionnaire.

3. Data collection and processing: Questionnaire responses will be analyzed and the responses will be statistically analyzed for correlation.

Benefits: Through participation in this study, patients may help future patients diagnosed with pyloric stenosis be brought to the attention of a medical professional.

Risks: With maintenance of confidentiality, risks to participants in this study are negligible.

Eligibility criteria: Inclusion Criteria:

* infants ages 2-9 weeks

Exclusion Criteria:

* infant not ages 2-9 weeks or patients with history of medical problems

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Maimonides Medical Center
state: New York
Study officials:
affiliation: Maimonides Medical Center
name: Beth Loveridge-Lenza, DO
role: PRINCIPAL_INVESTIGATOR
affiliation: Maimonides Medical Center
name: Maya Greenberg, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01729234: Effects of Dietary Nitrate on Age-related Vascular Function
Official title: Effects of Dietary Nitrate Supplementation on Age-related Vascular Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Endothelial Dysfunction
Keywords: age related Endothelial Dysfunction
Lead sponsor: Heinrich-Heine University, Duesseldorf
Sponsor class: OTHER
First posted: 2012-11-20
Enrollment: 20
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Purpose of the study is to characterize the chronic effect of dietary nitrate on vascular function in healthy volunteers with particular emphasis on age-related alterations.


Eligibility criteria: Inclusion Criteria:

\>55 Years Healthy

Exclusion Criteria:

known cardiovascular disease

Primary outcomes:
measure: Endothelial function measured by flow-mediated dilation (FMD)
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Duesseldorf,
country: Germany
facility: Heinrich-Heine-University
state: Nrw,
Study officials:
References: